

1 COVID-19 vaccination coverage and hesitancy among Australians with disability and long-
2 term health conditions

3

4 Zoe Aitken

5 Disability and Health Unit, Centre for Health Equity, Melbourne School of Population and
6 Global Health, The University of Melbourne

7

8 Eric Emerson

9 Institute for Health Research, Lancaster University

10

11 Anne Kavanagh

12 Disability and Health Unit, Centre for Health Equity, Melbourne School of Population and
13 Global Health, The University of Melbourne

14

15

16 **Abstract**

17 Background: COVID-19 vaccination is the cornerstone of managing Australia's COVID-19
18 pandemic and the success of the vaccination program depends on high vaccination coverage.
19 This paper examined differences in COVID-19 vaccination coverage and vaccine hesitancy
20 for people with disability, long-term health conditions, and carers – subgroups that were
21 prioritised in the vaccination program.

22

23 Methods: Using data from 2,400 Australians who participated in two waves of the Taking the
24 Pulse of the Nation survey in April and May 2021, we described vaccination coverage and
25 hesitancy among people with disability, severe mental health conditions, severe long-term
26 health conditions, frequent need for assistance with everyday activities, and carers,
27 disaggregated by age group and gender.

28

29 Findings: Vaccination coverage was estimated to be 8.2% in the sample overall and was
30 similar for people with disability, those with frequent need for assistance, and carers. It was
31 higher for people with severe long-term health conditions (13.4%) and lower for people with
32 severe mental health conditions (4.3%). Vaccine hesitancy was high overall (35.6%) and was
33 similarly high across the priority groups.

34

35 Interpretation: This study highlights the lack of a difference in vaccination coverage and
36 vaccine hesitancy for people with disability, long-term health conditions, and carers
37 compared to the general population. Sub-optimal vaccination coverage for people in the
38 priority population groups leaves many people at significant risk of serious disease or death if
39 exposed to COVID-19, particularly in light of the easing of disease-control restrictions across
40 Australia and the emergence of new COVID-19 variants.

41

42 Funding: National Health and Medical Research Council

43

44

45 **Introduction**

46 COVID-19 vaccination is the cornerstone of managing the COVID-19 pandemic. The
47 success of any vaccination program depends on high vaccination coverage and acceptance.
48 Across the world, countries implemented different strategies for the prioritisation of COVID-
49 19 vaccination. The World Health Organization (WHO) developed guidelines for the
50 prioritisation of vaccination among groups according to their risk of acquisition and
51 transmission of COVID-19 (e.g., health care workers providing direct care) and risk of
52 serious disease or death if infected by COVID-19 (e.g., older people, organ transplant
53 recipients).¹ WHO also recommended that the levels of community transmission in a country
54 should also guide vaccine distribution.¹

55

56 In Australia, the Commonwealth government has been responsible for the procurement and
57 distribution of COVID-19 vaccines and the policy settings, although there have been some
58 variations between States and Territories in the rollout to different groups. The
59 Commonwealth government prioritised a range of groups in Phase 1a, which commenced on
60 22 February 2021 and Phase 1b which commenced on 22 March 2021 (Table 1). People with
61 long-term health conditions including serious mental illness, people with intellectual
62 disability and people who required assistance with activities of daily living were prioritised.²
63 These groups also included workers providing support in aged-care or to people with
64 disability, as well as informal carers who provide unpaid support to people who needed
65 assistance with activities of daily living.

66

67

68

69

70 Table 1 Phase 1a and 1b priority groups

Phase 1a	Phase 1b
Aged care and disability care residents	People with long-term health conditions
Aged care and disability care staff	People with disability
Frontline health care workers	Carers
Quarantine and border workers	People aged 70 years and older
	Aboriginal and Torres Strait Islander Peoples aged 56 years and older
	Other health care workers
	Critical and high-risk workers

71

72 At the start of 2022, Australia had high COVID-19 vaccination coverage, ranked 15th
73 globally in terms of the proportion of the population vaccinated according to the Johns
74 Hopkins Coronavirus Resource Centre Vaccine Tracker.³ By mid-February 2022, 94.1% of
75 people aged 16 years and over had received two COVID-19 vaccine doses.⁴ However, the
76 vaccination coverage was substantially lower in some subgroups of the population at highest
77 risk of COVID-19 infection and morbidity, such as Aboriginal and Torres Strait Islander
78 Peoples (76.6%) and National Disability Insurance Scheme (NDIS) participants (86.1%),⁴
79 demonstrating large inequalities in vaccination coverage. Therefore, despite prioritising
80 people at highest risk, some priority groups have sub-optimal vaccination coverage which
81 poses a threat to individual and population immunity.⁵

82

83 People with disability and long-term health conditions are at high risk of serious disease or
84 death if infected with COVID-19 due to comorbidities, living conditions, behavioural factors
85 and socio-economic deprivation and may have higher risk of infection and transmission
86 because of their need for care or assistance and increased likelihood of living in congregate
87 care settings.^{6,7} But there is a lack of data describing COVID-19 vaccination rates for people
88 with disability and long-term health conditions because disability data are not routinely
89 collected in Australia. Data from government and media reports from mid-2021 showed that
90 there were significant delays in the rollout of the vaccine among people living in aged-care
91 and disability residences and the workers who support them.⁸⁻¹⁰ Since 21 January 2022, data
92 have been routinely reported on vaccination coverage for NDIS participants,¹¹ demonstrating
93 lower vaccine coverage compared to the general population, but this only represents 10% of
94 Australians with disability. There is a lack of data on vaccination coverage for the 90% of
95 Australians with disability who are not eligible for the NDIS.

96

97 There are several potential causes of low vaccination coverage for people with disability
98 including physical availability of vaccines, geographic accessibility, availability of accessible
99 information about vaccine availability and eligibility, and vaccine hesitancy.⁵ At the start of
100 the vaccination program, there was a lack of supply – a problem that intensified after the
101 Commonwealth government recommended that the Comirnaty (Pfizer/BioNTech) COVID-19
102 vaccine was used for people under 50 years on 8th April 2021 and then under 60 years on 16th
103 June 2021 because of the risk of Thrombosis with Thrombocytopenia Syndrome (TTS)
104 associated with the Vaxzevria (AstraZeneca) COVID-19 vaccine in younger age-groups.^{12,13}
105 Vaccine hesitancy, the delay in the acceptance or refusal of vaccines,^{5,14,15} is also a likely
106 cause of inequalities in vaccination coverage.

107

108 Australian research has demonstrated relatively high levels of vaccine hesitancy in the
109 population compared to similar countries.¹⁶ An Australian survey conducted in January 2021
110 before the vaccination program was implemented, found that only 44% of Australians
111 reported that they would definitely get vaccinated, with 35% reporting they would probably
112 get vaccinated, 8% reporting they would probably not get vaccinated, and 13% reporting they
113 would definitely not get vaccinated.¹⁷ More recent data from a longitudinal survey
114 investigating the impacts of the COVID-19 pandemic on Australian households which
115 collected data on disability and included questions about vaccine hesitancy in five waves of
116 the survey between December 2020 and July 2021 found that levels of vaccine hesitancy
117 were very similar between people with and without disability, though vaccine hesitancy was
118 higher for people with psychosocial disability.¹⁸

119

120 Australia experienced a surge in COVID-19 infections at the end of 2021 alongside the
121 easing of disease-control restrictions and the emergence of the Omicron variant, which
122 highlights the ongoing need for high COVID-19 vaccination coverage. Despite high
123 vaccination coverage in the population overall, waning vaccine immunity and sub-optimal
124 vaccination coverage in some subgroups of the population pose a threat to individual and
125 population immunity.⁵ Understanding inequalities in vaccine coverage and attitudes towards
126 vaccine hesitancy is important for tailoring vaccination programs and evidence-informed and
127 community-engaged responses to vaccine hesitancy to different subgroups.^{19,20} It is also
128 critical for understanding the potential impacts of easing restrictions on severe outcomes

129 associated with COVID-19 infection, which will be distributed inequitably across different
130 subgroups of the population.

131

132 This paper fills a gap in our knowledge about vaccination coverage and vaccine hesitancy
133 among people with disability and long-term health conditions, and carers in Australia with
134 the aim of identifying groups who require better targeting to improve vaccination coverage
135 and understanding the causes of sub-optimal vaccination coverage. Using data from 2,400
136 Australians who participated in Taking the Pulse of the Nation survey in April and May
137 2021, at the start of the COVID-19 vaccination program, we describe vaccination coverage
138 and hesitancy among people with disability, people who reported living with a severe mental
139 health condition, a severe long-term health condition, and those requiring frequent assistance
140 with everyday activities. We also report vaccination coverage and hesitancy for people who
141 provide paid or unpaid care to someone in one of the priority groups.

142

143 **Methods**

144 We used data from Taking the Pulse of the Nation (TTPN), a repeated cross-sectional survey
145 which has been conducted every two weeks since April 2020 by the Melbourne Institute:
146 Applied Economic & Social Research at the University of Melbourne. The survey was
147 implemented by a market research company Oz Info as a telephone or online interview,
148 collecting data from 1200 people at each wave to track Australians' expectations and
149 attitudes towards the COVID-19 pandemic. The sampling frame was constructed by Oz Info
150 from a diverse set of continuously updated proprietary databases. A stratified sampling
151 design was employed, dividing the population into strata defined by selected characteristics,
152 which were sampled separately to ensure representativeness of the underlying population of
153 interest.²¹ The strata were defined according to state of residence (all six states and the
154 Australian Capital Territory), location within each state (Greater Capital Area; other), gender
155 (men; women) and age group (18-24; 25-34; 35-44; 45-54; 55-64; 65-75; older than 75
156 years), with weights constructed to ensure the sample in each wave was representative of the
157 underlying population using ABS estimated resident population projections based on the
158 2016 Census.²² The TTPN survey was approved by the Human Research Ethics Committee at
159 the University of Melbourne (2021-14006-14669-1). The TTPN Survey data are available on
160 application to the Melbourne Institute: Applied Economic & Social Research at the
161 University of Melbourne.

162

163 This analysis used data from two waves of the survey conducted between 19 and 25 April
164 and between 10 and 14 May 2021 in which additional questions were included about
165 disability, long-term health conditions and caring responsibilities. At this stage of the
166 pandemic, people over the age of 50 years and people in high priority groups (and their
167 carers) were eligible to receive the vaccine (Table 1). In these two waves of the survey, a
168 question was included about presence of disability, defined as “a long-term health condition,
169 impairment or disability that restricts you in your everyday activities and has lasted (or is
170 likely to last) for 6 months or more”. Additional questions were included to identify whether
171 people had a severe mental health condition, a severe long-term health condition, or required
172 frequent assistance with everyday activities (e.g., eating, dressing, mobility), to align with the
173 vaccine priority group eligibility criteria. A question was also included to identify people
174 who provided care, help or assistance, either paid or unpaid, to people in the high priority
175 groups. Survey participants could tick multiple responses to these questions. For all
176 questions, responses “don’t know” were recoded to missing.

177

178 Information on vaccination and vaccine hesitancy was recorded in the survey. Participants
179 were asked if they were “willing to have the COVID-19 vaccine” with possible responses
180 listed as “I have had it already”, “yes”, “no”, and “don’t know”. People were identified as
181 being vaccinated if they responded that they had had the vaccine. Therefore, vaccination
182 coverage represents people who have had at least one dose of the vaccine. People were
183 identified as being vaccine hesitant if they responded “no” or “don’t know”, including both
184 vaccine refusers and those who may choose to delay, in accordance with the definition
185 derived by the SAGE Working Group on Vaccine Hesitancy.²³ People were identified as not
186 vaccine hesitant if they responded “yes” or were already vaccinated. We included people who
187 were vaccinated in the non-vaccine hesitant group to ensure valid comparisons of vaccine
188 hesitancy between subgroups of the population, independent of the proportion of people who
189 had been vaccinated.

190

191 Population subgroups of interest included age groups (18-64 years; 65 years and above) and
192 gender (men; women).

193

194 We estimated the proportion of the sample who were vaccinated and who were vaccine
195 hesitant, for the whole sample (both waves combined) and for exposure groups of interest
196 (people with disability, severe mental health conditions, severe long-term health conditions,

197 people requiring frequent assistance with everyday activities, and people who were paid or
198 unpaid carers). We disaggregated the results by age group and gender. Results were not
199 presented separately for each wave of the survey due to sample size limitations. The analyses
200 used survey weights, constructed using the most recent Australian Bureau of Statistics
201 estimated resident population projections based on the 2016 Census, stratified by gender, age
202 and location to be representative of the Australian population. Analyses were conducted in
203 Stata/SE 14.2 using the survey commands to account for the survey design characteristics.

204

205 **Results**

206 The two waves of the survey included 2,400 participants, of which 8.2% were vaccinated and
207 35.6% were vaccine hesitant (Table 2), comprising 19.1% who reported being unwilling to
208 get the vaccine and 16.5% who were unsure (data not shown).

209

210 Of the sample, 27.5% of participants had a disability, 10.8% had a severe mental health
211 condition, 19.9% had a severe long term health condition, 5.6% had frequent need for
212 assistance, and 26.4% were paid or unpaid carers. In terms of demographics, 20.2% of the
213 sample were aged 65 years and older, and 51% were women.

214

215 Table 2 Characteristics of the sample (n=2,400)

	n	%
Vaccinated		
Yes	177	8.2
No	2,223	91.8
Vaccine hesitancy		
Yes	854	35.6
No	1,546	64.4
Disability		
No	1,623	69.9
Yes	709	27.5
Missing	68	2.6
Severe mental health condition		
No	2,118	89.2
Yes	282	10.8
Missing	0	0
Severe long term health condition		
No	1,913	80.1
Yes	487	19.9
Missing	0	0
Frequent need for assistance		
No	2,258	94.4
Yes	142	5.6
Missing	0	0
Carer		
No	1,700	71.5
Yes	655	26.4

Missing	45	2.1
Age group		
18-64 years	1,942	79.8
65 years and older	458	20.2
Missing	0	0
Gender		
Men	1,200	49.0
Women	1,200	51.0
Missing	0	0

216 *Vaccination coverage*

217 Compared to the sample overall, the proportion of people who had been vaccinated was
 218 higher for people with severe long term health conditions (13.4%), similar for those with
 219 disability (8.9%), people in need of frequent assistance with everyday activities (7.1%), and
 220 carers (8.9%), and lower for people with severe mental health conditions (4.3%, Table 3).
 221 Vaccination coverage was similar for men (9.0%) and women (7.4%), and the patterns across
 222 the priority groups were broadly consistent with the sample overall when disaggregated by
 223 gender. Vaccination coverage was higher for people aged 65 years and older (30.5%)
 224 compared to those aged 18 to 64 years who had very low vaccination coverage (2.6%), even
 225 for people in the vaccine priority groups, ranging from 1.2% to 4.2%.

226

227 Table 3 Proportion of the study population who had received at least one dose of COVID-19
 228 vaccine, by priority group, age and gender

	Overall	Disability	Severe mental health condition	Severe long-term health condition	Frequent need for assistance	Carer
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Whole sample	8.2 (6.6, 9.8)	8.9 (6.8, 11.6)	4.3 (2.5, 7.5)	13.4 (9.9, 17.8)	7.1 (3.6, 13.4)	8.9 (6.4, 12.2)
Age						
18-64	2.6 (1.8, 3.6)	3.3 (2.0, 5.5)	2.3 (1.2, 4.5)	4.2 (2.4, 7.4)	1.2 (0.4, 3.8)	4.0 (2.2, 7.1)
65+	30.5 (24.9, 36.8)	27.5 (20.1, 36.4)	42.6 (19.1, 70.0)	32.7 (23.5, 43.4)	26.4 (12.1, 48.2)	26.2 (18.0, 36.5)
Gender						
Men	9.0 (6.9, 11.8)	10.7 (7.5, 15.0)	3.0 (1.2, 7.1)	14.0 (9.9, 19.5)	7.8 (3.2, 17.8)	8.4 (5.6, 12.4)
Women	7.4 (5.6, 9.7)	7.3 (4.8, 11.0)	5.9 (2.8, 11.7)	12.8 (7.9, 20.2)	6.1 (2.2, 16.0)	9.3 (5.8, 14.5)

229

230 *Vaccine hesitancy*

231 Overall vaccine hesitancy was high, with 35.6% of the sample estimated to be hesitant to
 232 receive the vaccine (Table 4). Vaccine hesitancy was found to be similarly high across the
 233 priority groups, ranging from 24.2% for people with frequent need for assistance to 36.1% for
 234 people with severe mental health conditions. Vaccine hesitancy was higher for people aged
 235 18 to 64 years (39.7%) compared to those aged 65 years and older (19.3%) and patterns
 236 within each age group were similar across the priority groups. There was a slight indication
 237 than vaccine hesitancy was higher for women than men (39.9% versus 31.1%).

238

239

240 Table 4 Proportion of the study population who were vaccine hesitant, by priority group, age
241 and gender

	Overall % (95% CI)	Disability % (95% CI)	Severe mental health condition % (95% CI)	Severe long-term health condition % (95% CI)	Frequent need for assistance % (95% CI)	Carer % (95% CI)
Whole sample	35.6 (33.2, 38.0)	30.3 (26.3, 34.7)	36.1 (29.4, 43.5)	27.7 (23.0, 33.0)	24.2 (16.6, 33.8)	30.7 (26.5, 35.2)
Age						
18-64	39.7 (37.0, 42.4)	34.7 (30.0, 39.8)	37.4 (30.4, 45.0)	32.9 (26.9, 39.6)	27.5 (18.5, 38.9)	34.3 (29.4, 39.6)
65+	19.3 (15.3, 24.1)	15.7 (10.6, 22.8)	12.3 (2.9, 39.1)	16.7 (11.0, 24.6)	13.4 (5.0, 31.2)	18.0 (11.8, 26.4)
Gender						
Men	31.1 (27.9, 34.5)	28.1 (22.6, 34.4)	30.3 (21.3, 41.0)	27.1 (20.4, 35.0)	25.6 (14.9, 40.3)	22.8 (17.5, 29.1)
Women	39.9 (36.5, 43.4)	32.3 (26.7, 38.6)	42.8 (33.1, 53.1)	28.2 (21.8, 35.6)	22.5 (13.6, 34.9)	36.3 (30.3, 42.8)

242

243 Discussion

244 The findings of this study suggest that vaccination coverage was similar between people in
245 the overall sample and the majority of the priority groups examined in this study, including
246 people with disability, people with frequent need for assistance and people who were carers.
247 There was some evidence that vaccination coverage was higher for people with severe long-
248 term health conditions and lower for people with severe mental health conditions.
249 Vaccination coverage was strikingly low for younger people in all priority groups. Given that
250 people in these priority groups were eligible to receive the vaccine at the time of the survey,
251 the lack of difference in vaccination coverage between young people in the priority groups
252 and the overall sample is surprising and of concern.

253

254 Despite people with disability being prioritised for vaccination, the Royal Commission
255 hearing in May 2021 highlighted the low rates of vaccination for people with disability.²⁴ The
256 results of this study were consistent with the findings of the Royal Commission, indicating
257 low vaccination coverage and little evidence of a difference in vaccination coverage for
258 people with disability and long term health conditions compared to the overall sample.

259

260 Our study found that vaccination coverage was higher for people aged 65 years and older
261 compared to those aged 18 to 64 years. Older adults aged 70 years and older became eligible
262 for vaccination in phase 1b, which explains the higher coverage among older people in the
263 sample, driven by age-based eligibility. This suggests the presence of additional barriers to
264 achieving high vaccination coverage for people with disability and long-term health
265 conditions for whom eligibility for vaccination did not translate into higher vaccination
266 coverage.

267

268 We found evidence of high levels of vaccine hesitancy overall with more than one in three
269 people in the sample reporting that they were hesitant to receive a COVID-19 vaccine. There
270 were high levels of vaccine hesitancy for people in the priority groups, particularly for young
271 people, despite their elevated risk of serious illness or death if they contracted COVID-19. It
272 is important to note that data for the first of the two waves of the survey were collected just
273 after the change in the Commonwealth government recommendation that people under 50
274 years were to receive the Cominraty (Pfizer/BioNTech) vaccine rather than the Vaxzevria
275 (AstraZeneca) vaccine because of the risk of TTS. This announcement may account, in part,
276 for the elevated vaccine hesitancy reported in this study, particularly for young people.
277 Indeed, vaccine hesitancy in the first wave for which data were available on priority groups
278 was estimated to be 39% overall, notably higher than previous and subsequent waves of the
279 TTPN survey where vaccine hesitancy was 32% on average, ranging from 29% to 35%. The
280 estimates of vaccine hesitancy are consistent in magnitude with statistics published by the
281 government which suggest that vaccine hesitancy in Australian adults peaked in April and
282 May 2021 and then gradually declined.²⁵ Given Australia's current high vaccination rates,
283 vaccine hesitancy at the start of the vaccination program has not translated into vaccine
284 refusal for a large proportion of the population. However, data are not currently available on
285 the trajectory of vaccination uptake (and vaccine hesitancy) for people with disability and
286 long-term health conditions, which may be different to the overall population.

287

288 Given the lack of difference in vaccine hesitancy between people with disability and long-
289 term health conditions and the overall sample, it is unlikely that the low vaccination coverage
290 for people with disability and long-term health conditions is due to increased vaccine
291 hesitancy. Reports from disability organisations and media have suggested that people with
292 disability experienced multiple barriers, including problems securing appointments, lack of
293 accessible information about eligibility and availability of vaccines, and finding accessible
294 vaccination clinics.^{26,27} The lack of research examining reasons for low vaccination coverage
295 is an important evidence gap, and important to address for COVID-19 vaccination but also
296 for other vaccines.

297

298 Our study had a number of strengths. This is the first study to examine vaccination coverage
299 and hesitancy for people with disability and long-term health conditions in Australia, using
300 definitions aligning closely with the vaccine priority groups. The sample was large enough to

301 identify people in all the priority groups of interest, including analyses disaggregated by age
302 group and gender. There were also limitations. We did not examine all vaccine priority
303 groups. There was insufficient data to examine occupational vaccine priority groups such as
304 healthcare workers, though it would be valuable to gain insights into vaccination coverage
305 and hesitancy in these groups who were also eligible to receive the vaccine. We only
306 examined two broad age groups because there were too few younger people in the priority
307 groups to disaggregate the age groups further. As a result, we could not examine people aged
308 younger than 50 years separately, for whom there were different recommendations for use of
309 the Cominraty (Pfizer/BioNTech) vaccine. Further, due to the age categories used in the
310 survey, it was not possible to identify people aged 70 years and above to align with age-based
311 eligibility. We did not examine differences by other socio-demographic characteristics
312 including ethnicity, Aboriginal and Torres Strait Islander peoples, or cultural and linguistic
313 diversity because the survey did not collect data on these characteristics. Given the evidence
314 about differences in vaccine hesitancy by ethnicity in the United Kingdom and the United
315 States²⁸ but not found in New Zealand²⁹ it is important to examine differences in vaccine
316 hesitancy according to ethnicity for people in priority groups in future research. Participation
317 rates could not be estimated in this study, therefore it was not possible to assess the impact of
318 potential selection bias from non-participation. Due to its relatively small sample, the survey
319 is unlikely to be representative of the Australian population, though the sample weights make
320 the results more representative of the population. The vaccine coverage was estimated to be
321 8.2% overall, which is broadly consistent, though perhaps slightly lower, than population
322 estimates of vaccination coverage at similar time points, estimated to be 7.5% on 25th April
323 2021 and 12.1% on 16th May 2021.³⁰

324

325

326 **Conclusions**

327 This study highlights the lack of a difference in vaccination coverage in the first few months
328 of Australia's COVID-19 vaccination program between people with disability and long-term
329 health conditions who were prioritised in the COVID-19 vaccination program and the general
330 population. The results are concerning because low vaccination coverage for people in the
331 priority population groups leaves many people at significant risk of serious disease or death if
332 exposed to COVID-19, particularly in light of the easing of disease-control restrictions across
333 Australia once population vaccination targets were achieved and the emergence of new
334 COVID-19 variants.

335

336 Recent data are needed to analyse current inequalities in vaccination coverage between
337 people with disability and long-term health conditions compared to the overall population
338 statistics to contrast the results from the start of the vaccination program with the current
339 situation in which Australia has reached high vaccination coverage in the population overall.
340 Furthermore, data should be routinely collected to report on vaccination coverage for people
341 with disability and long-term health conditions.

342

343 Vaccine hesitancy was found to be similar between people with disability and long-term
344 health conditions compared to the overall sample, suggesting that low vaccination coverage is
345 likely to be caused by barriers to accessing vaccination rather than high vaccine hesitancy.
346 There remains a lack of understanding of the barriers faced by people in these priority
347 groups. Further research is needed to understand the barriers to accessing COVID-19
348 vaccination experienced by Australians with disability and long-term health condition, to
349 generate the information that is needed to devise effective strategies to improve uptake by
350 ensuring these populations have easy access to COVID-19 vaccines such as accessible
351 vaccination hubs, in-reach into workplaces and homes, and co-designed communication
352 strategies.

353

354 **Authors' contributions**

355 ZA, AK and EE conceived the study and designed the questions for the TTPN Survey. ZA
356 analysed the data and results were reviewed and interpreted by ZA, AK and EE. ZA and AK
357 wrote the manuscript, which was reviewed by EE.

358

359 **Conflict of interest statement**

360 The authors have no conflicts of interest.

361

362 **Funding**

363 This study was funded by a National Health and Medical Research Council Centre of
364 Research Excellence grant (1116385). The funders of the study had no role in the design of
365 the study, data collection, data analysis, data interpretation, or writing of the manuscript.

366

367 **Ethics committee approval**

368 The Taking the Pulse of the Nation Survey was approved by the Human Research Ethics
369 Committee at the University of Melbourne (2021-14006-14669-1).

370 **References**

- 371 1. World Health Organization. WHO SAGE roadmap for prioritizing the use of COVID-19
372 vaccines in the context of limited supply: an approach to inform planning and subsequent
373 recommendations based upon epidemiologic setting and vaccine supply scenarios. CC BY-
374 NC-SA 3.0 IGO. Geneva: World Health Organization, 2020.
- 375 2. Commonwealth Department of Health. Australia's COVID-19 vaccine national roll-
376 out strategy. . 2020.
377 [https://www.health.gov.au/sites/default/files/documents/2021/01/covid-19-vaccination-](https://www.health.gov.au/sites/default/files/documents/2021/01/covid-19-vaccination-australia-s-covid-19-vaccine-national-roll-out-strategy.pdf)
378 [australia-s-covid-19-vaccine-national-roll-out-strategy.pdf](https://www.health.gov.au/sites/default/files/documents/2021/01/covid-19-vaccination-australia-s-covid-19-vaccine-national-roll-out-strategy.pdf).
- 379 3. Johns Hopkins Coronavirus Resource Centre. Vaccination progress across the world.
380 2021. <https://coronavirus.jhu.edu/vaccines/international> (accessed 04/08/2021 2021).
- 381 4. Australian Government Operation COVID Shield. COVID-19 Vaccine Rollout, 15
382 February 2022. 2022.
383 [https://www.health.gov.au/sites/default/files/documents/2022/02/covid-19-vaccine-](https://www.health.gov.au/sites/default/files/documents/2022/02/covid-19-vaccine-rollout-update-15-february-2022.pdf)
384 [rollout-update-15-february-2022.pdf](https://www.health.gov.au/sites/default/files/documents/2022/02/covid-19-vaccine-rollout-update-15-february-2022.pdf) (accessed 15 February 2022 2022).
- 385 5. Bedford H, Attwell K, Danchin M, Marshall H, Corben P, Leask J. Vaccine hesitancy,
386 refusal and access barriers: The need for clarity in terminology. *Vaccine* 2018; **36**(44): 6556-
387 8.
- 388 6. Sabatello M, Landes SD, McDonald KE. People With Disabilities in COVID-19: Fixing
389 Our Priorities. *The American Journal of Bioethics* 2020; **20**(7): 187-90.
- 390 7. Boyle CA, Fox MH, Havercamp SM, Zubler J. The public health response to the
391 COVID-19 pandemic for people with disabilities. *Disability and Health Journal* 2020; **13**(3):
392 100943.
- 393 8. Clay L. Two-thirds of staff in aged care homes not vaccinated. *The Age*. 2021
394 26/06/2021.
- 395 9. Henriques-Gomes L. 'Abject failure': only 999 out of 26,000 Australian disability care
396 residents vaccinated. *The Guardian*. 2021 17/05/2021.
- 397 10. Senator the Hon Linda Reynolds CSC. NDIS COVID-19 vaccine rollout update [press
398 release]: Ministers for the Department of Social Services, 2021.
- 399 11. Australian Government Operation COVID Shield. COVID-19 Vaccine Rollout, 21
400 January 2022. 2022.
401 [https://www.health.gov.au/sites/default/files/documents/2022/01/covid-19-vaccine-](https://www.health.gov.au/sites/default/files/documents/2022/01/covid-19-vaccine-rollout-update-21-january-2022.pdf)
402 [rollout-update-21-january-2022.pdf](https://www.health.gov.au/sites/default/files/documents/2022/01/covid-19-vaccine-rollout-update-21-january-2022.pdf) (accessed 15 February 2022 2022).
- 403 12. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
404 Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med* 2021; **384**(22): 2092-
405 101.
- 406 13. Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after
407 ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021; **384**(22): 2124-30.
- 408 14. MacDonald NE, Sage Working Group on Vaccine Hesitancy. Vaccine hesitancy:
409 Definition, scope and determinants. *Vaccine* 2015; **33**(34): 4161-4.
- 410 15. Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the
411 fight against COVID-19. *Eur J Epidemiol* 2020; **35**(8): 775-9.
- 412 16. Ipsos. Global attitudes: COVID-19 vaccines. 2021. [https://www.ipsos.com/en-](https://www.ipsos.com/en-ba/global-attitudes-covid-19-vaccine-january-2021)
413 [ba/global-attitudes-covid-19-vaccine-january-2021](https://www.ipsos.com/en-ba/global-attitudes-covid-19-vaccine-january-2021) (accessed 09/02/2021 2021).
- 414 17. Biddle N, Edwards B, Gray M, Sollis K. Change in vaccine willingness in Australia:
415 August 2020 to January 2021. *medRxiv* 2021: 2021.02.17.21251957.
- 416 18. ABS. People with disability: Household impacts of COVID-19. Canberra: ABS, 2022.

- 417 19. Butler R, MacDonald NE. Diagnosing the determinants of vaccine hesitancy in
418 specific subgroups: The Guide to Tailoring Immunization Programmes (TIP). *Vaccine* 2015;
419 **33**(34): 4176-9.
- 420 20. Strully KW, Harrison TM, Pardo TA, Carleo-Evangelist J. Strategies to Address COVID-
421 19 Vaccine Hesitancy and Mitigate Health Disparities in Minority Populations. *Front Public*
422 *Health* 2021; **9**: 645268.
- 423 21. Cesar CC, Carvalho MS. Stratified sampling design and loss to follow-up in survival
424 models: evaluation of efficiency and bias. *BMC Med Res Methodol* 2011; **11**: 99.
- 425 22. ABS. National, state and territory population. Canberra: ABS, 2021.
- 426 23. MacDonald NE, Hesitancy SWGoV. Vaccine hesitancy: Definition, scope and
427 determinants. *Vaccine* 2015; **33**(34): 4161-4.
- 428 24. Royal Commission into Violence, Abuse, Neglect and Exploitation of People with
429 Disability. Public hearing 12: The experiences of people with disability, in the context of the
430 Australian Government's approach to the COVID 19 vaccine rollout. Sydney, 2021.
- 431 25. Australian Government Operation COVID Shield. COVID-19 Community Sentiment
432 Monitor: Summary (Jan-22). 2022.
433 [https://www.health.gov.au/sites/default/files/documents/2022/02/operation-covid-shield-](https://www.health.gov.au/sites/default/files/documents/2022/02/operation-covid-shield-covid-19-vaccine-sentiment-summary-january-2022-covid-19-community-sentiment-monitor-summary-january-2022_0.pdf)
434 [covid-19-vaccine-sentiment-summary-january-2022-covid-19-community-sentiment-](https://www.health.gov.au/sites/default/files/documents/2022/02/operation-covid-shield-covid-19-vaccine-sentiment-summary-january-2022-covid-19-community-sentiment-monitor-summary-january-2022_0.pdf)
435 [monitor-summary-january-2022_0.pdf](https://www.health.gov.au/sites/default/files/documents/2022/02/operation-covid-shield-covid-19-vaccine-sentiment-summary-january-2022-covid-19-community-sentiment-monitor-summary-january-2022_0.pdf) (accessed 17 February 2022 2022).
- 436 26. People with Disability Australia. People With Disability Struggle To Access COVID
437 Vaccine. 2021. <https://pwd.org.au/people-with-disability-struggle-to-access-covid-vaccine/>
438 (accessed 17 February 2022 2022).
- 439 27. Gearin M. People with disabilities facing multiple barriers in Australia's coronavirus
440 vaccine rollout. ABC News. 2021 21 May 2021.
- 441 28. Khan MS, Ali SAM, Adelaide A, Karan A. Rethinking vaccine hesitancy among minority
442 groups. *Lancet* 2021; **397**(10288): 1863-5.
- 443 29. Prickett KC, Habibi H, Carr PA. COVID-19 Vaccine Hesitancy and Acceptance in a
444 Cohort of Diverse New Zealanders. *Lancet Reg Health West Pac* 2021; **14**: 100241.
- 445 30. Commonwealth Department of Health. COVID-19 vaccine rollout updates. . 2021.
446 <https://www.health.gov.au/resources/collections/covid-19-vaccine-rollout-updates>.
447